首页> 外文期刊>The Journal of Urology >Analysis of cathepsin D forms and their clinical implications in human prostate cancer.
【24h】

Analysis of cathepsin D forms and their clinical implications in human prostate cancer.

机译:组织蛋白酶D形式及其在人类前列腺癌中的临床意义的分析。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To assess cathepsin D (Cat.D) status in the prostate, we analyzed the different Cat.D forms in human prostate tissues using Western immunoblots. MATERIALS AND METHODS: Cell extracts were prepared from prostate tissues (n = 42) obtained from radical prostatectomy, adopting the tissue homogenization method. Expression of the different Cat.D forms was analyzed using Western blots. The catalytic activity of Cat.D was assayed by acid treatment, in which cell extracts were incubated in acidic buffer (pH 3 to 4) at 37C for 1 hour. RESULTS: Pathologically confirmed normal (NML), benign prostatic hyperplasia (BPH) and cancer (CAP) specimens all expressed Cat.D, but as two distinct forms. Both NML and BPH predominantly expressed an inactive procathepsin D (Pro.Cat.D), while CAP notably exhibited an active mature Cat.D. The assessment of Cat.D activity, using PSA (prostate specific antigen) as a physiological substrate, showed that such activity was consistently higher in CAP than in NML/BPH specimens. Further studies revealed that the mode of Cat.D activation in CAP specimens appeared to be primarily due to acid-induced autoproteolysis (self-degradation) of mature Cat.D. CONCLUSION: This study demonstrates that expression and activity of Cat.D varies among prostate specimens. A greater expression of mature Cat.D with a higher catalytic activity in CAP specimens is the most notable difference from NML/BPH. Therefore, the differential expression/activity of Cat.D forms may be a useful indicator for assessing prostate cancer status.
机译:目的:为了评估组织蛋白酶D(Cat.D)在前列腺中的状态,我们使用Western免疫印迹分析了人类前列腺组织中不同的Cat.D形式。材料与方法:采用组织均质化方法,从前列腺癌根治术的前列腺组织(n = 42)中制备细胞提取物。使用蛋白质印迹分析不同Cat.D形式的表达。通过酸处理测定Cat.D的催化活性,其中将细胞提取物在酸性缓冲液(pH 3至4)中于37℃温育1小时。结果:经病理证实的正常(NML),良性前列腺增生(BPH)和癌症(CAP)标本均表达Cat.D,但以两种截然不同的形式表达。 NML和BPH都主要表达无活性的组织蛋白酶D(Pro.Cat.D),而CAP则表现出有活性的成熟Cat.D。使用PSA(前列腺特异性抗原)作为生理底物对Cat.D活性的评估显示,CAP中的这种活性始终高于NML / BPH标本。进一步的研究表明,CAP标本中Cat.D的活化方式似乎主要是由于酸诱导的成熟Cat.D的自蛋白水解(自降解)。结论:这项研究证明Cat.D的表达和活性在前列腺标本中有所不同。 CAP标本中具有较高催化活性的成熟Cat.D的更大表达是与NML / BPH的最显着差异。因此,Cat.D形式的差异表达/活性可能是评估前列腺癌状态的有用指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号